The Use of Sulfasalazine in Severe Types of Alopecia Areata

Piyanuch Chairerg, Pravit Asawanonda*, Maturada Kongkabpan, Sukamas Suwanwalaikorn and Wirach M Taungjaruwini

Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Abstract
Extensive types of alopecia areata (AA), especially alopecia totalis (AT) and alopecia universalis (AU) are notoriously difficult to treat. Recently, sulfasalazine has shown a promising result with well-tolerated side effects through immunomodulatory and anti-inflammatory effects. Several studies reported desirable response among AA patients who failed other treatments. This article reviews the previous studies of sulfasalazine in AA in terms of its efficacy as well as other aspects including mode of action, indications, contraindications, dosage, administration, drug interaction as well as monitoring.

Keywords: Alopecia areata; Sulfasalazine; Hair loss

Abbreviations: AA: alopecia areata; AT: Alopecia Totalis; AU: Alopecia Universalis; IL: Interleukin.

Introduction
With prevalence ranging from 0.7 % to 3.8% of patients attending dermatology centers in different populations, [1,2] alopecia areata is undoubtedly a common disease. There is no sex or ethnic predilection and it may occur at any age, however, the majority commence before 20 years [3]. Intriguingly, up to 85% of Asian patients develop AA before 40 years of age [4]. Although the majority of patients present with a sudden onset of patchy hair loss that re-grows spontaneously without any scars within a year [5,6], AA in up to 10% of patients may progress into more chronic and extensive forms [5].

Despite its commonness, the exact pathophysiology of AA remains largely unknown. At present, it is believed to be an autoimmune and inflammation-driven disease. Hence, it is commonly associated with myriads of other autoimmune conditions including thyroid diseases, e.g. Graves’s disease and Hashimoto’s thyroiditis [7,8], vitiligo [9], diabetes as well as myasthenia gravis [10].

The loss of hair in AA is related to alterations in the normal cycle of hair growth, with shifting of follicular stages from anagen to catagen, and in turn telogen. Typically, miniaturized hair follicles and inflammatory infiltrates comprising predominantly lymphocytes at peribulbar region are seen on histology [11-14]. CD and CD T cells are believed to be involved in this mechanism and the extents of hair loss have been shown to correlate with the ratio of these cells [15]. Moreover, both cell subsets are involved in AA induction and persistence, at least in the mouse models [16,17].

Besides T cells, several clinical and experimental studies point toward defects in cytokine production or signaling that might induce hair loss in AA, the processes in which interleukin (IL) -1 [18], -2 [19], -6 [20] and tumor necrosis factor alpha (TNFα) [18] have been demonstrated to be involved. Recently, the pathogenesis of AA has been extensively reviewed by Alkhalfah et al. [21]

Wide-used modalities of treatment include corticosteroids in virtually all modes of administration, topical sensitizers, anthralin, minoxidil, PUVA and even 308-nm excimer laser. However, none of these has yielded consistent results and the recalcitrant and extensive AA, especially AT and AU are notoriously difficult to treat. Recently, sulfasalazine was described in a few reports with promising outcomes in these perplexing types of AA [22-26].

History
Sulfasalazine was first developed in 1938 for the treatment of rheumatoid arthritis [27] for which it is now categorized as a disease-modifying antirheumatic drug (DMARD). It is also used in various diseases in which T lymphocytes are involved in pathophysiology such as inflammatory bowel disease, psoriasis and scleroderma among others.

Mode of action of sulfasalazine
Although sulfasalazine has been used for many decades, the precise mechanism of action has not been fully elucidated, nor is it clear whether the parent drug and/or its metabolites, namely sulfapyridine and 5 aminosalicylic acid, are principally responsible for its beneficial effects. Following oral administration, the pro-drug is inactive. Only upon reaching the colon where it is degraded by bacterial azoreductases, is when sulfapyridine and 5-aminosalicylic acid released. All 3 moieties, i.e. sulfasalazine, sulfapyridine and 5-aminosalicylic acid, are extensively metabolized.

The action of sulfasalazine in autoimmune diseases is most likely mediated by either immunomodulatory or anti-inflammatory effects [28]. For immunomodulatory effects, several in vitro studies have shown that sulfasalazine and/or its metabolites inhibit the release of cytokines produced by various cell types, especially T-lymphocytes which are responsible for IL-2 induction and monocytes/macrophages, responsible for IL-1, IL-6, IL-12 and tumor necrosis factor (TNF)-α induction [29-31]. Possibly through regulations of these cytokines, as well as T-cell proliferation, natural killer cell activity and activation of B cells, sulfasalazine halts AA progression [28].

For anti-inflammatory effects, sulfasalazine has been shown to inhibit chemotaxis and random migration of inflammatory cells such as neutrophils, and reduce superoxide and proteolytic enzyme production [28]. An in vitro study suggested sulfasalazine might also exert a slight inhibitory effect by modulating prostaglandin E2 synthetase activity [29].

Received September 26, 2011; Accepted October 31, 2011; Published November 23, 2011

Citation: Chairerg P, Asawanonda P, Kongkabpan M, Suwanwalaikorn S, Taungjaruwini WM (2011) The Use of Sulfasalazine in Severe Types of Alopecia Areata. Hair : Therapy & Transplantation 1:102. doi:10.4172/2167-0951.1000102

Copyright: © 2011 Chairerg P. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Indications and contraindications

The challenge of AA treatment is the fact that although many treatment modalities are available, none can change its natural course. Safety of the medication when used long-term is thus, of utmost importance. In this regard, sulfasalazine may have an important role as there are reports on successful and safe use of sulfasalazine in inducing hair regrowth in AT and AU in both adults and children [22-26]. It has also been used as a sole agent in the maintenance phase of treatment.

Contraindications and warnings/precautions for the use of sulfasalazine in the treatment of AA are summarized in Table 1.

Therapeutic efficacy of sulfasalazine for AA

In an extensive records review by Ellis et al., wherein 16% of 249 evaluable AA patients were treated with sulfasalazine, cosmetically acceptable hair regrowth took place in 23% of the subjects [24]. Among those who completed a course of sulfasalazine, 80% with limited AA had excellent benefit while only 21.43% of patients with AT/AU had similar responses. Complete regrowths were also observed [26]. In 2008 Aghaei and co-workers from Iran reported the efficacy of sulfasalazine in 22 evaluable patients with recalcitrant AA or severe AA with more than 40% hair loss, in an open-label study. The duration of treatment ranged from 6 to 24 months, including some patients who required long-term treatments to maintain hair regrowth. Approximately two-thirds of the patients responded to treatment, among these 27.3% showed complete hair regrowth. In all, 36.4% of treated subjects had more than 40% hair loss, in an open-label study. The duration of treatment ranged from 6 to 24 months, including some patients who required long-term treatments to maintain hair regrowth. Approximately two-thirds of the patients responded to treatment, among these 27.3% showed complete hair regrowth. In all, 36.4% of treated subjects had 50% hair regrowth or more [22]. The largest prospective study was also reported from Iran in the same year. Using the very same protocol, Rashidi et al. demonstrated the efficacy of sulfasalazine in 39 patients with alopecia areata in whom 43.6% had 50% hair regrowth or more. When different extents of AA were analyzed, 51.7% with patchy alopecia had 50% hair regrowth whereas only 20% of AT patients had such results [26]. The authors also pointed out that patients whose disease onset was during childhood had less favorable response to the treatment. Despite the successful treatment, hair loss recurred in 25% to 45.5% of cases in the above studies. This usually took place a few months after termination of therapy [22,26] but had also occurred even during maintenance treatment [22].

Apart from the extent of hair loss and age at onset, which are the 2 most predictive prognostic factors in AA, it is clear from the above-mentioned reports that response to sulfasalazine seems to be somewhat dose-dependent. In many subjects in Ellis and co-workers’ report, the response was not seen at dosages under 3g/day. Moreover, when doses were reduced hair loss ensued and stopped when doses were escalated [24]. This agrees well with our experience. Also, the duration of treatment is of importance, as hair regrowth often takes 3-5 months to occur or to be cosmetically appreciated [23,24].

It is rather difficult to compare the results of sulfasalazine with other therapeutic agents due to the paucity of information in the English literature. Most reports on systemic agents as monotherapy comprise only case series, whilst in others they are used in combination with corticosteroids [32]. However, sulfasalazine seems to compare favorably with cyclosporine monotherapy [33].

Dosage and administration

Sulfasalazine is available in an oral form as 500mg enteric-coated tablets. Gradual dose escalation is desired to minimize gastrointestinal side effects. In rheumatoid arthritis, sulfasalazine is started at 500 mg/day and increased weekly to optimal therapeutic range at 2-3 g/day taken twice a day, preferably with meals. Among AA studies, most patients are initially prescribed at a dosage of 1 g daily with increments of 1 g monthly until optimal doses of 3-4 g/day are reached. If the result is desirable, it can be maintained at these dosages for at least 3-7 months [22,23,25,26]. However, some authors recommend more rapid dose escalation such as weekly as employed in rheumatoid arthritis [24].

Combination therapy: Corticosteroid is commonly used as a first drug to halt the progression of active AA, however, high relapse rate after discontinuation and long-term side effects are valid concerns. One strategy to lessen relapse after discontinuation is combination with sulfasalazine. This combination is logical as the 2 agents have different mechanisms of action and more importantly, distinct adverse effect profiles. In a report by Bakar and Gurbuz, 6 patients with AA resistant to previous treatments with a range of disease duration from 3 to 20 years, were treated with sulfasalazine in combination with oral corticosteroids with desirable outcome [23]. Duration of the combination was 2-6 months, following which the corticosteroids were withdrawn and sulfasalazine monotherapy ranging from 4 to 12 months was used to sustain the initial hair regrowth. Interestingly, some patients maintained the regrowth hair after discontinuation of sulfasalazine. No severe side effects were detected [23]. Although there are limited data of this combination it should be considered as an alternative choice for refractory disease.

Drug Interaction

Drug-drug interaction

Sulfasalazine reduces absorption of digoxin resulting in decreased effectiveness of the latter. When sulfasalazine is combined with sulfonylureas special attention needs to be paid due to decreased elimination of the hypoglycemic agents by the liver resulting in excessive reductions in plasma glucose. The risk of kidney damage from cyclosporine increases when it is combined with sulfasalazine by unknown mechanisms. A byproduct of sulfasalazine, sulfapyridine, increases blood levels of methotrexate contributing to increased methotrexate toxicity. Moreover, methotrexate can worsen anemia caused by sulfonamide as both deplete folates. Sulfapyridine also enhances the anticoagulant effect of warfarin resulting in deterioration of controlled international normalized ratio (INR) level. As a result, close monitoring of anticoagulant activity is necessary for this combination. Paradoxically, there is a case report of recurrent deep-vein thrombosis due to warfarin resistance in ulcerative colitis treated with sulfasalazine [34] (Table 2).

Combining 5-aminosalicylic acid with nonsteroidal anti-inflammatory drugs may increase the risk of renal dysfunction. Lastly,

---

Table 1: Contraindications and warnings/precautions for sulfasalazine.

Contraindications:
- Hypersensitivity to sulfonamides or salicylates
- Age < 2 years
- Gastrointestinal tract/Gerintourinary tract obstruction
- Porphyria

Warnings/precautions:
- Bloody dyscrasia
- Hepatic impairment
- Renal impairment
- Severe asthma
- Pregnancy and lactation
- G6PD deficiency
concurrent use of 5-aminosalicylic acid and 6-mercaptopurine or azathioprine could result in higher risks of bone marrow suppression [35,36].

Drug-food interaction

Sulfasalazine decreases folic acid absorption from food which may cause folate deficiency and result in anemia [37,38]. One mg/day of folic acid is, therefore, recommended for those taking sulfasalazine to prevent anemia.

Adverse Effects

Sulfasalazine has a relatively good safety profile. Adverse effects in most cases occur in the first 3 months of therapy and are well-tolerated [39,40] (Table 3). Nevertheless, approximately 20-30% of patients encountered adverse events severe enough to result in discontinuation of treatment [24,29,40]. Fatal side effects of sulfasalazine are rare and usually develop within 2–6 weeks after initiation of the medication. These include the “three-week syndrome”, which is characterized by fever, lymphadenopathy and widespread erythematous rash, followed by severe hepatotoxicity [40]. The more serious reaction, DRESS syndrome, does not occur frequently, however, physicians should perform a close observation especially during the early phase of therapy [40,41].

Many side effects are associated with high serum levels of sulfapyridine which depends on acetylator phenotype [39,42]. Common side effects are gastrointestinal disturbances (nausea, vomiting, diarrhea, decreased appetite, anorexia) and central nervous system effects (dizziness and headache) which account for 66.6% of the reported adverse events in a large prospective study [43]. Skin eruption is reported in 4–5% of patients taking sulfasalazine [24,44]. Hematologic dysfunctions, e.g., leukopenia are reported in less than 3% of sulfasalazine recipients. However, up to 50% of those patients who received high dose sulfasalazine (4–6 gm/day) demonstrate evidence of hemolysis [39]. Photosensitivity has been reported in rare cases. Other less common adverse effects include various blood dyscrasias, fever, arthralgia, dyspepsia and hepatic dysfunctions.

Sulfasalazine and sulfapyridine can cross the placenta. Sulfasalazine can be a valuable alternative treatment option in AA patients treated with sulfasalazine will achieve good to excellent response. Serious adverse reactions from sulfasalazine even in long-term use or when combined with other treatments are rare. However, a close clinical and laboratory monitoring is recommended especially at the initial period of treatment.

Summary

Sulfasalazine can be a valuable alternative treatment option in AA patients who are resistant to other therapeutic modalities. It acts through immunomodulatory and anti-inflammatory effects. Sulfasalazine may be prescribed as monotherapy or combined with other therapies especially corticosteroid. Approximately one quarter of AA patients treated with sulfasalazine will achieve good to excellent response. Serious adverse reactions from sulfasalazine even in long-term use or when combined with other treatments are rare. However, a close clinical and laboratory monitoring is recommended especially at the initial period of treatment.

References

1. Sharma VK, Dawn G, Kumar B (1996) Profile of alopecia areata in Northern India. Int J Dermatol 35: 22-27.
2. Tan E, Tay YK, Goh CL, Chin Giam Y (2002) The pattern and profile of alopecia areata in Singapore-a study of 219 Asians. Int J Dermatol 41: 748-753.
3. Price VH (1991) Alopecia areata: clinical aspects. J Invest Dermatol 96: 68S.
4. Safavi K (1992) Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 128: 702.
5. Madani S, Shapiro J (2000) Alopecia areata update. J Am Acad Dermatol 42: 549-566.
6. Alexis AF, Dudda-Subramanya R, Sinha AA (2004) Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol 14: 364-370.
7. Puuvali S, Puuvali G, Charuwichitratana S, Sakuntabhai A, Sriprachya-Anunt S (1994) Prevalence of thyroid diseases in patients with alopecia areata. Int J Dermatol 33: 632-633.
8. Kurtev A, Iliev E (2005) Thyroid autoimmunity in children and adolescents with alopecia areata. Int J Dermatol 44: 457-461.
9. Lu W, Shapiro J, Yu M, Barekatain A, Lo B, et al. (2006) Alopecia areata: pathogenesis and potential for therapy. Expert Rev Mol Med 8: 1-19.
10. McElwee KJ, Boggess D, Olivry T, Oliver RF, Whiting D, et al. (1998) Comparison of alopecia areata in human and nonhuman mammalian species. Pathobiology 66: 90-107.
11. Elston DM, McCollough ML, Bergfeld WF, Liranzo MO, Heibel M (1997) Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of alopecia areata. J Am Acad Dermatol 37: 101-106.
12. Whiting DA (1995) Histopathology of alopecia areata in horizontal sections of scalp biopsies. J Invest Dermatol 104: 265-275.
13. McDonagh AJ, Messenger AG (1996) The pathogenesis of alopecia areata. Dermatol Clin 14: 661-670.
14. Messenger AG, Slater DN, Bleehen SS (1996) Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. Br J Dermatol 114: 337-347.
15. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A (2007) Alopecia areata. Int J Dermatol 46: 121-131.
16. McElwee KJ, Spiers EM, Oliver RF (1986) In vivo depletion of CD8+ T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol 135: 211-217.
17. Carroll JM, McElwee KJ, E King L, Byrne MC, Sundberg JP (2002) Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol 119: 392-402.
18. Philpott MP, Sanders DA, Bowen J, Kealey T (1996) Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. Br J Dermatol 135: 942-948.
19. Freyschmidt-Paul P, McElwee KJ, Hoffmann R, Sundberg JP, Kissling S, et al. (2005) Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in C3H/HeJ mice. J Invest Dermatol 125: 945-951.
20. Lortkipanidze NT, Tevzadze M, Kamkamidze GK (2005) Interferon-gamma and neopterin in alopecia areata. Georgian Med News 53-57.
21. Alkhalfah A, Alsantali A, Wang E, McElwee KJ, Shapiro J (2010) Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 62: 177-188.
22. Aghaei S (2005) Reduced expression of interleukin-10 decreases the frequency of alopecia areata onset in C3H/HeJ mice. J Invest Dermatol 125: 945-951.
23. Bakar O, Gurbuz O (2007) Is there a role for sulfasalazine in the treatment of alopecia areata? J Am Acad Dermatol 57: 703-706.
24. Ellis CN, Brown MF, Voorhees JJ (2002) Sulfasalazine for alopecia areata. J Am Acad Dermatol 46: 541-544.
25. Misyary L, Sannier K, Chastaign M, Le Gallic G (2007) Treatment of alopecia areata with sulfasalazine. J Eur Acad Dermatol Venereol 21: 547-548.
26. Rashidi T, Mahd AA (2008) Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol 47: 850-852.
27. Bachrach WH (1988) Sulfasalazine: I. An historical perspective. Am J Gastroenterol 83: 487-496.
28. Smedegard G, Bjork J (1995) Sulfasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 34: 7-15.
29. Losker GL, Croom KF (2005) Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 65: 1825-1849.
30. Kang BY, Chung SW, Im SY, Choe YK, Kim TS (1999) Sulfasalazine prevents T-helper 1 immune response by suppressing interleukin-12 production in macrophages. Immunology 98: 96-103.
31. Rodenbujg RJ, Ganga A, van Lent PL, van de Putte LB, van Vrooij WJ (2000) The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum 43: 1941-1950.
32. Alkhalfah A, Alsantali A, Wang E, McElwee KJ, Shapiro J (2010) Alopecia areata update: part II. Treatment. J Am Acad Dermatol 62: 191-202.
33. Gupta AK, Ellis CN, Cooper KD, Nickloff BJ, Ho VC, et al. (1990) Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol 22: 242-250.
34. Teefy AM, Martin JE, Kovacs MJ (2000) Warfarin resistance due to sulfasalazine. Ann Pharmacother 34: 1265-1268.
35. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, et al. (2001) Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalazine, sulfasalazine, or balsalazide. Gut 49: 656-664.
36. Dewit O, Vanheverzwyn R, Desager JP, Horsmans Y (2002) Interaction between azathioprine and aminosaliclyates: an in vivo study in patients with Crohn’s disease. Aliment Pharmacol Ther 16:79-85.
37. (1988) Sulfasalazine inhibits folate absorption. Nutr Rev 46: 320-323.
38. Halsted CH, Gandhi G, Tamura T (1981) Sulfasalazine inhibits the absorption of folates in ulcerative colitis. N Eng J Med 305: 1513-1517.
39. Cunliffe RN, Scott BB (2002) Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 16: 647-662.
40. Suresh R, Gupta S, Sathananthan R (2009) Sulfasalazine induced three-week syndrome. J Clin Rheumatol 15: 311-312.
41. Aquino RT, Vergueiro CS, Magliari ME, de Freitas TH (2008) Sulfasalazine-induced DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms). Sao Paulo Med J 126: 225-228.
42. Azad Khan AK, Howes DT, Piris J, Truelove SC (1980) Optimum dose of sulfasalazine for maintenance treatment in ulcerative colitis. Gut 21: 232-240.
43. Donovan S, Hawley S, MacCarthy J, Scott DL et al. (1990) Tolerability of enteric-coated sulfasalazine in rheumatoid arthritis: results of a co-operating clinics study. Br J Rheumatol 29: 201-204.
44. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, et al. (2001) Treatment of active rheumatoid arthritis with lefunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 60: 913-923.
45. Norgard B, Czeizel AE, Rockenbauer M, Olsen J, Sørensen HT (2001) Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15: 483-486.
46. Alonso V, Linares V, Bellés M, Albina ML, Sirvent JJ, et al. (2009) Sulfasalazine pregnancy. Aliment Pharmacol Ther 15: 483-486.
47. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15: 483-486.
48. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15: 483-486.
49. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15: 483-486.